为解决 CAR-T 细胞疗法存在的诸多问题，如成本高、毒性大等，浙江大学医学院附属第二医院等机构的研究人员开展了 4-1BB 共刺激 CD19 特异性 CAR-NK 细胞（CD19-BBz CAR-NK）治疗难治 / 复发大 B 细胞淋巴瘤的 1 期临床试验。结果显示该疗法安全可行，能诱导持久缓解 ...

为探究 CD19-CAR-T 细胞疗法对人体组织 B 细胞的影响以及抗抑郁药治疗腰腿痛的效果，研究人员开展相关研究。结果显示，CD19-CAR-T 细胞疗法可深度清除组织 B 细胞；抗抑郁药对腰腿痛效果各异。这为相关疾病治疗提供新依据。 在医学研究的长河中，自身免疫性 ...

By drastically enhancing the effectiveness of CD19 CAR T-cell therapies against lymphoma cells with low or no CD19 antigen expression, Aleta is set to increase B-cell cancer cure rates significantly.

“CLN-978 is the only CD19-targeting T cell engager advancing a global regulatory development plan that includes a US FDA-cleared IND. Delivering the potency of T cell redirecting therapy with the ...

Clinical-grade CAR-T cell manufacturing was performed in a closed system using a second-generation CD19 vector with 41BB costimulatory domain. Quality control was assessed at different points in the ...